Attitudes of African-Americans regarding prostate cancer clinical trials
Tóm tắt
Từ khóa
Tài liệu tham khảo
American Cancer Society. Cancer Facts and Figures 1995.American Cancer Society, Incorporation. Publication No. 5008, 1995, pp 10–12.
Miller BA, Ries LAG, Hankely BF, Kosary CL, Harras A, Devesa SS, and Edward BK (Eds).SEER Cancer Statistics Review: 1973–1990, National Cancer Institute. NIH Publication No. 93-2789, 1994.
Kurihara M, Aoki K, and Hisamichi S (Eds).Cancer Mortality Statistics in the World 1950–1985. Nagoya, Japan; University of Nagoya Press, 1984.
Flemming C, Wasson JH, Albersen PC, Barry MJ, and Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer: prostate Patient Outcomes Research Team.JAMA 1993; 269:2650–2658.
Moskovitz B, Nitecki A, and Richter L. Cancer of the prostate: is there a need for aggressive treatment?Urology Int 1987; 42:49–52.
George NR. Natural history of localized prostatic cancer managed by conservative therapy alone.Lancet 1988; 1:494–497.
Handley R, Carr TW, Travis D, Powell PH, and Hall RR. Deferred treatment for prostate cancer.Br J Urol 1988; 62:249–253.
Chodak GW, Thisted RA, Berber GS, and et al. Results of conservative management of clinically localized prostate cancer.New Eng J Med 1994; 330:242–248.
Elder J, Jeweet H, and Walsh P. Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate.J Urol 1983; 127:704–706.
Goodman C, Busuttil A, and Chisholm G. Age and size and grade of tumor predict prognosis in incidentally diagnosed carcinoma of the prostate.Br J Urol 1988; 62:576–580.
Whitmore W, Warner J, and Thompson I. Expectant management of localized prostatic cancer.Cancer 1991; 67:1091–1097.
Johansson JE, Adami HO, Anderson SO, and et al. High 10 year survival rate in patients with early untreated prostatic cancer.JAMA 1992; 267:2191–2196.
Zaluzny A, Brawley O, Garson-Angert D, and et al. Assuring access to state of the art care for US minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program.J Natl Cancer Inst 1993; 85: 1945–1950.
Lee JY, Marks JE and Simpson JR. Recruitment of patients to Cooperative Group Clinical Trials.Cancer Clin Trials 1980; (3) 381–384.
Lee JY and Breaux SR. Accrual of radiotherapy patients to clinical trials.Cancer 52:1014–1016, 1983.
Martin J, Henderson R, Zacharski L, and et al. Accrual of patients into a multihospital cancer clinical trial and its implications on planning future studies.Am J Clin Oncol 1984; 7:173–182.
Begg CV, Carborbe PP, Elson PJ, and et al. Participation of community hospitals in clinical trials: analysis of five years of experience in the Eastern Cooperative Oncology Group.New England J Med 1983; 306:1076–1080.
Hunter CP, Frelick RW, Feldman AR, and et al. Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician's Patient Log.Cancer Treat Reports 1987; 71: 559–563.
Barbie, E.The Practice of Social Research. Belmont, CA: Wadsworth, 1989, pp. 20–29.
Dignan M, Michielutte R, Sharp P, Bahnson J, Young L, and Beal P. The role of focus groups in health education programs for cervical cancer among minority groups.J Comm Health 1990; 15:369–375.
Morgan DL, and Kruger RA. When to Use Focus Groups and Why? In. Morgan DL (Ed).Successful Focus Groups: Advancing the State of the Art. Sage Publications, Newburg CA: 1993, pp 3–19.
Myers RE, Thomas WA, Balshiem AM, Ross EA and Chodak GW. Receptivity of African-American men to prostate cancer screening.Urology 1994; 43:480–487.
Davis SW, Nealson ED, and Stone JC. Evaluation of the National Cancer Institute's Clinical Trial Booklet.Journal of the National Cancer Institute Monographs 1993; 14:193–195.